Please login to the form below

Not currently logged in
Email:
Password:

iGlarLixi

This page shows the latest iGlarLixi news and features for those working in and with pharma, biotech and healthcare.

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan) combines top-selling basal insulin Lantus (insulin glargine) – albeit now facing biosimilar competition in some markets - and

Latest news

  • Sanofi trumpets new IGlarLixi data after regulatory delay Sanofi trumpets new IGlarLixi data after regulatory delay

    Sanofi trumpets new IGlarLixi data after regulatory delay. Reports that the combination drug is more effective at controlling glucose than Lantus alone. ... Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is

  • Sanofi loses lead on diabetes combo IGlarLixi after FDA delay Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

    Sanofi loses lead on diabetes combo IGlarLixi after FDA delay. FDA verdict on Novo Nordisk’ s rival combo Xultophy due next month . ... The FDA is due to deliver a verdict on Xultophy next month, with a decision on IGlarLixi now pushed out to the end

  • Sanofi boosted by iGlarLixi trials at ADA Sanofi boosted by iGlarLixi trials at ADA

    Sanofi boosted by iGlarLixi trials at ADA. Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes. ... The positive data comes as iGlarLixi approaches an FDA decision on approval - due in August - after a positive

  • FDA panel backs Sanofi's insulin/GLP-1 agonist combo FDA panel backs Sanofi's insulin/GLP-1 agonist combo

    FDA panel backs Sanofi's insulin/GLP-1 agonist combo. iGlarLixi secures endorsement despite concern over its dosing and delivery device. ... iGlarLixi and other new drugs such as longer-acting Lantus follow-up Toujeo are considered key to Sanofi's

  • FDA advisors back Novo Nordisk's IDeglira combination FDA advisors back Novo Nordisk's IDeglira combination

    The committee's decision could also give Novo a boost over its diabetes rival Sanofi, whose similar combination of iGlarLixi (which brings together Lantus and Lyxumia) is due to be reviewed

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics